TEL-AVIV, Israel and RALEIGH, N.C. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal ...
RedHill to receive $30 million following closing to support its commercial operations, including the planned launch of Talicia ® this quarter and the ongoing promotion of Aemcolo ® RedHill will receive an additional $50 million to fund the acquisition of rights to Movantik ® from AstraZeneca ...
RedHill to promote Movantik ® in the U.S. upon closing Movantik ® generated U.S. net sales of $96 million in 2019 Acquisition financing to be provided by HealthCare Royalty Partners (HCR) as part of the $115 million non-dilutive financing TEL-AVIV, Israel and RALEIGH, N.C. , Feb. ...
TEL-AVIV, Israel and RALEIGH, N.C. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal ...
RedHill is on track to launch Talicia ® in the U.S. in the first quarter of 2020 for the treatment of H. pylori infection in adults - - - RedHill to sponsor H. pylori medical education event at the Pri-Med South Conference scheduled for February 6-9, 2020 - - - RedHill to sponsor the No Stomach ...
TEL-AVIV, Israel and RALEIGH, N.C. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the ...
TEL-AVIV, Israel and RALEIGH, N.C. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the ...
Aemcolo ® (rifamycin) is a non-systemic antibiotic delivered directly to the site of non-invasive E. coli infection in the lower intestine Aemcolo ® is approved by the FDA for the treatment of travelers’ diarrhea, and is covered by a robust U.S. patent portfolio which, together with the U.S. ...
Key Highlights: U.S. FDA approval of Talicia ® for the treatment of Helicobacter pylori infection in adults Strategic partnership with Cosmo Pharmaceuticals , including investment of $36.3 million and exclusive rights to commercialize Aemcolo ® in the U.S. ...
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 15, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for ...
Menu